RELAPSED AND REFRACTORY MM ELDERLY PATIENT WITH RENAL IMPAIRMENT

Is SARCLISA + Pd appropriate for your RRMM patients?

Meet Mary – A patient with relapsed and refractory MM with disease progression on 3L treatment

Age
76 years old
Gender
Female
Time since MM diagnosis
6 years
R-ISS stage at diagnosis
Stage II

Initial treatment

  • Mary was ineligible for ASCT and treatment was initiated with the cyclophosphamide, thalidomide, dexamethasone (CTd) regimen

Disease progression

  • Mary’s disease progressed after three years
  • Mary received second-line treatment with the carfilzomib, dexamethasone (Kd) regimen and achieved a VGPR
  • Two years later Mary’s disease progressed and third-line treatment with lenalidomide and dexamethasone (Rd) was initiated
  • At a regular check-up, Mary reported back pain and weight loss. Disease progression was demonstrated at this time and Rd treatment was discontinued

Additional patient information

Cytogenetic risk
Standard
Bone marrow plasma cells
70%
Hg
12 g/dL
Beta-2 microglobulin
5.5 µL/mL
Renal function (CrCl)
45 mL/min/1.73 m2
Would Mary be a candidate for treatment with SARCLISA + Pd?

Mary would be eligible for treatment with SARCLISA + Pd1,2

Percentage of patients receiving SARCLISA + Pd in the ICARIA-MM trial with similar baseline characteristics2

You are now leaving the https://sarclisa.co.uk website.

By clicking on this link, you will be leaving this Sanofi hosted website, and, depending on the link, will be redirected to either another Sanofi website (for example, to view the Sanofi Privacy Policy) or an independent third-party website.
Sanofi has no control over the content or availability of third-party sites or resources that are linked to, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. The existence of a link between this website and any third party site or resource in no way implies that Sanofi in any way approves of the content of these sites or resources, or any use to which such content maybe put.

Please ensure that you read the legal and privacy policy sections of any website to which you link.

CONTINUE